No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ITOS240517C11000
- 7.00
- 0.000.00%
15min DelayTrading May 17 15:04 ET
0.00High0.00Low
0.00Open7.00Pre Close0 Volume0 Open Interest11.00Strike Price0.00Turnover6650.73%IV1.07%PremiumMay 17, 2024Expiry Date6.81Intrinsic Value100Multiplier-3DDays to Expiry0.19Time Value100Contract SizeAmericanOptions Type0.8840Delta0.0203Gamma2.54Leverage Ratio-40.2326Theta0.0000Rho2.25Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
ITeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on ITeos Therapeutics, Raises Price Target to $46
ITeos Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 156.98% HC Wainwright & Co. $44 → $46 Maintains Buy 03/12/2024 50.84% JP Morgan $29 → $27 Maint
ITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment Data
By Ben Glickman Shares of iTeos Therapeutics rose sharply after the company said one of its tumor treatment clinical trials had shown promising interim results. The stock was up 47% to $17.86 in Fri
Comments
$ITeos Therapeutics(ITOS.US$ Everyday some derpy stock with "therapeutics" in its name goes up 50%. we get it.
3
Jill DeSimone's appointment to iTeos' Board of Directors is a significant move. Her oncology expertise and business growth record are expected to contribute to iTeos' late-stage biopharmaceutical ambitions.
Read more